New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Discover how iX Biopharma's patented drug delivery technology is driving its growth and expanding its product portfolio ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...
H2 2025: Request meeting with FDA to discuss 505(b)(2) pathway. H2 2025: Target submission of New Drug Application (NDA). Sublingual ED medication H1 2026: Finalize formulation and manufacture test ...
Format Comparison for Needle-Free GLP-1 Options, Administration Preferences, and Telehealth Access PathwaysHOUSTON, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational ...
Verywell Health on MSN
Routes of medication administration
Prescription drugs can be administered in various ways. This includes oral (by mouth), enteral (into the gastrointestinal ...
H1 2026: Finalize formulation and manufacture test product. H1 2026 Initial Phase 1 pharmacokinetic clinical cross-over study. "Our pipeline is focused on research in therapeutic areas where we can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback